NEWS
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
ZyVersa Therapeutics (ZVSA) announces publication of research demonstrating that its Inflammasome ASC Inhibitor IC 100 restored retinal structure and function in a Retinopathy of Prematurity (ROP) animal model.
The study, published in Angiogenesis, showed that IC 100 suppressed retinal microglia activation, attenuated inflammation, abnormal vascularization, and retinal thinning.
Key findings include:
IC 100 decreased expression of inflammasome-related molecules and inflammatory cytokines
It reduced ASC speck formation and microglial activation
Structural and functional improvements correlated with corrections of hyperoxia-modulated gene pathways
IC 100 decreased expression of inflammasome-related molecules and inflammatory cytokines
It reduced ASC speck formation and microglial activation
Structural and functional improvements correlated with corrections of hyperoxia-modulated gene pathways
This research supports IC 100's potential in treating ROP, a leading cause of childhood blindness worldwide, and adds to its promising indications including early Alzheimer's disease, multiple sclerosis, and acute respiratory distress syndrome.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1075Followers
68Following
7395Visitors
Follow